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In the last decade, LMTK3 (lemur tyrosine kinase 3) has emerged as an impor-
tant player in breast cancer, contributing to the advancement of disease and the
acquisition of resistance to therapy through a strikingly complex set of mech-
anisms. Although the knowledge of its physiological function is largely
limited to receptor trafficking in neurons, there is mounting evidence that
LMTK3 promotes oncogenesis in a wide variety of cancers. Recent studies
have broadened our understanding of LMTK3 and demonstrated its impor-
tance in numerous signalling pathways, culminating in the identification
of a potent and selective LMTK3 inhibitor. Here, we review the roles of
LMTK3 in health and disease and discuss how this research may be used to
develop novel therapeutics to advance cancer treatment.1. Introduction
LMTK3 (lemur tyrosine kinase 3) has gained attention in recent years due to the
growing evidence of its involvement in a multitude of cancers [1–35]. While
initially identified to have a role in ERα (oestrogen receptor alpha) regulation in
breast cancer [19], LMTK3 is now known to fuel tumourigenesis through many
diverse mechanisms. LMTK3, also known as LMR3 or AATYK3, belongs to the
LMTK (LMR or AATYK) family of kinases, along with LMTK1 (also known as
LMR1 or AATK) and LMTK2 (also known as LMR2, BREK, KPI2 or AATYK2).
This family of kinases performs a wide range of functions in cell signalling and
membrane trafficking, while aberrancies in these proteins are linked to diseases
such as cystic fibrosis, Alzheimer’s disease and cancer [36–40]. Importantly,
LMTK3 has been found to be overexpressed in several cancer subtypes, where
it contributes to the progression of the disease. LMTK3 mutations have also
been identified; however, their clinical significance is yet to be elucidated.
About 50% of the identified mutations are missense mutations, while nonsense
mutations only occur in 1.71% of the cases (table 1) [41,42].
LMTK3, located at 19q13.33 on chromosome 19, encodes a 1489 amino acid
protein (NP_001073903.1) that consists of a kinase domain (aa 162–aa 440), a
transmembrane helical segment and a large intrinsically disordered region
(IDR), which extends to the end of the C-terminus. Despite its nomenclature,
LMTK3 mainly acts as a serine/threonine kinase and phosphorylates various
substrates involved in ERα expression and stability, trafficking, gene regulation
and oncogenesis as discussed below. The low complexity of the IDR and high
homology with other LMTK family members suggest that LMTK3 may possess
many unidentified roles beyond those already explored. In addition to its
kinase activity, LMTK3 has also been shown to work as a scaffold protein, reg-
ulating gene expression. It was described as a ‘randomly created’ scaffold due
to the absence of classical scaffolding regions; however, proline-rich domains in











adrenal gland 0 0.75 15.19 n.t.
stomach 3.51 0.21 11.93 n.t.
oesophagus 1.24 0.39 9.6 n.t.
pancreas 0.81 n.t 9.5 n.t.
urinary tract 1.87 0.5 6.86 n.t.
lung 1.29 n.t. 6.58 0
thyroid 3.84 n.t. 5.46 n.t.
large intestine 4.07 n.t. 5.41 n.t.
liver 3.02 0.15 5.36 21.72
soft tissue 0.17 0.38 5.32 n.t.
prostate 1.62 n.t. 4.62 2.51
CNS 0.35 0.19 1.15 n.t.
upper aerodigestive tract 2.22 n.t. 4.02 n.t.
cervix 3.37 0.33 3.58 n.t.
breast 1.31 0.34 3.44 0.42





the C-terminus may also enable interaction with SH3
domain-containing proteins [43]. The physiological functions
of LMTK3 are poorly characterized as most reports focus on
LMTK3 aberrancies in different cancers and the predictive
and prognostic relevance of LMTK3. Nevertheless, LMTK3
has been studied in normal physiology and proposed to
have important trafficking roles in neurons where LMTK3
knockout has a profound impact on the behaviour of mice.
The complex roles played by LMTK3 highlighted the need
to solve its crystal structure to support drug discovery efforts.
A number of in silico approaches have been attempted to
model the kinase domain of LMTK3 and subsequently identify
potential inhibitors [44–48]; however, the determination of the
crystal structure of the kinase domain by our group represents
the key milestone in the field [33]. This research ultimately led
to the discovery of a potent and selective LMTK3 inhibitor,
namely, ‘C28’. This compound slowed cancer growth in
xenograft models, demonstrating the therapeutic potential of
pharmacological LMTK3 inhibition. Through further struc-
tural and functional studies, this significant finding will
accelerate the translation of this research into the clinic with
great promise to improve cancer therapy.2. The physiological function of LMTK3
One of the more well-characterized physiological functions of
LMTK3 is its neurological role. All members of the LMTK
family are expressed in the brain, suggesting that they play
an important role in the central nervous system (CNS).
Kawa et al. [49] reported distinct expression patterns between
LMTK1, LMTK2 and LMTK3 in the brains of mice. Specifi-
cally, LMTK1 was found to be ubiquitously expressed in
all regions of the brain, while LMTK2 and LMTK3 were
mainly expressed in the cerebral cortex, striatum, cerebellum,hippocampus, olfactory bulb and tubercle. Tomomura et al.
[50] also highlighted subtle differences in the regional and
subcellular localization patterns of different LMTK family
members in mouse brains and suggested that they may be
involved in the regulation of apoptosis and neurite extension.
Largely consistent with the above studies, LMTK3 was
found to be expressed in the thalamus, cerebral cortex and
hippocampus of mice, which provided further evidence that
LMTK3 is likely to play a role in the CNS [51]. Specifically,
this study found that LMTK3 is expressed in layers II to VI
of the cerebral motor cortex and areas CA1–3 and dentate
gyrus of the hippocampus. Inoue et al. [51] attempted to
characterize the function of LMTK3 in the CNS in vivo.
LMTK3−/−micewere compared towild-typemice and hetero-
zygotes in a number of behavioural tasks. LMTK3−/− mice
showed a significant increase in hyperactivity in both novel
and acquainted environments compared to their heterozygous
andwild-type counterparts. This study also carried out behav-
ioural experiments to assess anxiety. The elevated plus maze
is often used in mouse experiments to assess the effectiveness
of medications in treating anxiety. Spending more time in
the open arm activity and making more visits to the open
arms indicates a lower level of anxiety in mice [52]. Inoue
et al. [51] found that LMTK3−/− mice spent significantly
more time in open arms and entered the open arms more
frequently than wild-types.
The forced swim test [53] and the tail suspension assay [54]
are used to study depression-like behaviour in rodents. In both
behavioural assays, the LMTK3−/− mice displayed hyperloco-
motion when compared to thewild-types, and it was therefore
suggested that the LMTK3−/− mice had less depression-like
behaviour [51]. However, as the knockout mice exhibited a
hyperactive phenotype, these assays may not be a reliable
measure of depression since hyperactivity/attention deficit




3observed differences as ADHD has features of hyperactivity,
impulsiveness and inattention [55,56].
Dopamine is also suggested to play a role inADHD-like be-
haviour [57]. Dopamine is a neurotransmitter which, among
others, controls reward, cognition, movement and mood [58].
The dopamine transporter (DAT) reuptakes synaptic dopa-
mine thereby reducing extracellular dopamine levels [59].
DAT−/− mice are used as a model for ADHD. DAT−/− mice
have higher levels of extracellular dopamine and display a
unique phenotype primarily characterized by hyperlocomo-
tion [60]. Methylphenidate, a licensed medication for the
treatment of ADHD, increases synaptic levels of dopamine
through reuptake inhibition [61]. Paradoxically, methylpheni-
date has a calming effect on DAT−/− mice [62]. LMTK3−/−
mice had increased levels of striatal dopamine metabolism,
suggesting a possible explanation for their hyperlocomotion;
however, when LMTK3−/− mice were treated with methylphe-
nidate, they still exhibited a more hyperactive phenotype than
their wild-type counterparts [51]. These data suggest that
the pathophysiology of hyperlocomotion in LMTK3−/− differs
from ADHD and the DAT−/− model.
The N-methyl-D-aspartate receptor (NMDA-R) is involved
in neuronal plasticity and excitotoxicity [63]. LMTK3-deficient
cultured neurons have been shown to have increased levels of
intracellular GluN1 and GluN2B subunits of the NMDA-R
but the total and surface levels of the receptors were not
significantly different to the control [51]. Inoue et al. [51]
suggested that LMTK3 has a role in the trafficking of the
NMDA-R and that the total number of surface receptors is the
same because of homeostatic mechanisms, which detect the
level of receptor expression on the cell surface, as is the case
forAMPA(α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid) receptors [64].
The NMDA-R is also implicated in psychiatric conditions
such as mood disorders and schizophrenia [65–67]. A recent
study looked at the role of LMTK3 in psychiatric conditions.
In this follow-up work, further behavioural experiments of
the LMTK3−/− mice were carried out and it was suggested
that the knockout mice exhibited behavioural characteris-
tics associated with schizophrenia and bipolar disorder [68].
Specifically, the knockout mice had cognitive defects, loss of
novelty preference, deficits in prepulse inhibition and hyper-
sociability. Lower sociability [69] and depression [70] are
frequent clinical findings in patients with schizophrenia.
However, in the initial behavioural experiments described
above, the LMTK3−/− mice showed a phenotype of reduced
depression [51]. Therefore, this evidence suggests that the
LMTK3−/− mice could be exhibiting a behavioural pattern
consistent with overlapping bipolar and schizophrenia-like be-
haviour [68]. Schizoaffective-like behaviour has a mixture of
both mood and psychotic symptoms [71], and the LMTK3−/−
mice could resemble this disease.
Clozapine is an antipsychotic used for treating schizo-
phrenia. When LMTK3−/− mice were treated with acute
doses of clozapine, they showed improvement in learning
andmemory [68].Moreover, the same study also demonstrated
that while glutamate A1 (GluA1) expression was reduced in
the forebrain of the knockouts, the levels of GluA1 were
increased when treated with clozapine. Electrophysiological
experiments also revealed impairment of long-term poten-
tiation in the knockout mice and reduced GluA1 trafficking
post-AMPA stimulation [68]. These studies suggest an impor-
tant role for LMTK3 in trafficking, in line with the functionsof other LMTK family members; however, more research is
needed into the specific role played by LMTK3.
The potassium chloride co-transporter (KCC2) also plays
an important role in neurons through the extrusion of Cl− to
maintain a low intracellular chloride concentration, enabling
GABAA (type-A γ-aminobutyric acid) receptor- and glycine
receptor-mediated post-synaptic inhibition. Potentiation of
KCC2 has been proposed as a strategy to treat both epilepsy
and neuropathic pain due to its role in counteracting the
pathological hyperexcitability of neurons in these disease
states [72]. Using immunoprecipitation of KCC2 complexes,
followed by blue native polyacrylamide gel electrophoresis
(BN-PAGE) coupled with LC-MS/MS, Smalley et al. [73]
identified three stable protein complexes containing KCC2,
isolated from the mouse forebrain. LMTK3 was detected in
the largest of these complexes. The phosphorylation sites of
KCC2 were also mapped, revealing 11 phosphosites, one
of which matched the consensus sequence for LMTK3
(ESRGS940) that is described below. Although the function
of LMTK3 in this complex was not determined, it may
represent an important additional role of LMTK3 in the CNS.
Overall, given the widespread expression of LMTK3 in the
brain, it is likely to play a crucial role in the CNS. To date,
studies on LMTK3 and the CNS are very limited and the
exact physiological role of LMTK3 in the CNS remains
unknown, although LMTK3 is proposed to be involved in
GluA1 trafficking. LMTK3−/− mice might be a valuable
model in trying to both understand the pathophysiology of
schizoaffective disorders both at the neuronal network level
but also to study the effect of novel antipsychotic medications.
Future experiments are needed at a molecular level to under-
stand the exact mechanism through which LMTK3 regulates
GluA1. Finally, the comparison of LMTK3−/− mice to wild-
types through in vivo two-photon imaging will be invaluable
in further deciphering the specific roles of LMTK3 in the CNS.3. The intricate role of LMTK3 in cancer
LMTK3 has been implicated in a broad range of cancers, both
as a key component of a variety of oncogenic pathways and as a
useful predictive and prognostic biomarker (table 2). Although
much of the research performed to date has shown LMTK3 to
be an oncogene in breast cancer, as extensively described
below, LMTK3 was initially found to be linked to leukaemia.
In 2009, Tyner et al. [1] identified LMTK3 as a potential target
in chronic neutrophilic leukaemia (CNL) since patient-derived
CNL cells carrying the JAK2 V617F mutation were sensitive to
LMTK3 silencing. A previous tyrosine kinome siRNA study in
acute myeloid leukaemia (AML) did not identify LMTK3 as a
target, highlighting the heterogeneityof cancers and the impor-
tance of identifying relevant populations for specific therapies
[76]. Nevertheless, LMTK3may be a useful target to explore in
blood cancers.
Several studies have also highlighted a role for LMTK3
in brain tumours. Fazi et al. [2] investigated the miRNome
and transcriptome of glioblastoma (GBM) tissues and peri-
tumoural regions with the aim of identifying molecular
pathways involved in overall survival. LMTK3 was among
the possible targets the authors found. Evaluation of the data
at themRNAand protein levels confirmed that LMTK3 is over-
expressed in tumoural tissues and peritumoural regions
compared to healthy white matter [2]. Somatic mutation of
Table 2. Identification and characterization of LMTK3 in various types of
cancer (in alphabetical order). CNL, chronic neutrophilic leukaemia; CRC,
colorectal cancer; GBM, glioblastoma multiforme; GIST, gastrointestinal
stromal tumour; NB, neuroblastoma; NSCLC, non-small-cell lung cancer;



















LMTK3 has been identified in neuroblastoma patients; how-
ever, the clinical significance of these mutations was not
investigated [3].
LMTK3 has been identified as a contributor to both the
development and progression of lung cancer. As ERα also has
prognostic value in lung cancers, studies have explored
LMTK3 as a potential lung cancer biomarker [77]. Higher
levels of serum LMTK3 were found in non-small-cell lung
cancer (NSCLC) patients, compared to healthy individuals
and those with benign lung lesions [4]. Similar results were
obtained by Zhang et al. [5] in 2015 where it was additionally
shown that NSCLC tissue had a higher abundance of LMTK3
compared to healthy lung tissue. Furthermore, LMTK3 has
been reported to have a role as a putative transformation sup-
pressor in NSCLC as LMTK3 shRNA resulted in increased
anchorage-independent growth as measured by the soft agar
colony formation assay [6]. Although the hit was not validated,
it may suggest that LMTK3 plays a tumour suppressor role in
the early development ofNSCLCbefore taking on an oncogenic
role inmore advanced disease. These studies emphasize the rel-
evance of LMTK3 as both a potential target and a biomarker in
cancer; however, more research is needed into the specific role
played by LMTK3 and the balance between its oncogenic and
transformation-suppressing functions.
A role of LMTK3 in thyroid malignancies was also
described by Lu et al. [7]. ERα is overexpressed in thyroid can-
cers and oestrogen antagonists have been proposed as a
treatment [78]; therefore, LMTK3, as a modulator of ERα,
may represent a useful target in thyroid carcinomas. The
authors found that serum LMTK3 was more abundant in
patients with more advanced disease. In addition, tissue
samples had a higher abundance of LMTK3 mRNA and
protein in malignant thyroid tumours compared to benign
lesions. Using the SW579 squamous cell thyroid carcinoma
cell line, they found that LMTK3 silencing decreased invasive-
ness and promoted apoptosis. This study suggests that LMTK3may play an important role in promoting invasion and cell
survival in thyroid cancer [7].
The role of LMTK3 has been widely investigated in gastro-
intestinal stromal tumours (GISTs). KIT is a receptor tyrosine
kinase activated by the ligand stem cell factor (SCF). Mutant
KIT is a key driver of GIST growth; therefore, the inhibition
of KIT by imatinib is effective in improving patient survival;
however, imatinib resistance is a major problem in GIST
treatment. Using a human kinome siRNA screen, LMTK3
was identified to have a role as a novel KIT regulator in KIT-
mutant GIST and melanoma cells. Klug et al. found that
LMTK3 regulates the translation of KIT. Loss of LMTK3 in
GIST resulted in a decrease in total KIT and a reduction in its
downstream signalling, promoting cell death in the GIST430
line [8]. In 2013, Wakatsuki et al. [9] found that in a Japanese
male cohort of gastric cancer patients, the LMTK3 polymorph-
ism rs9989661 (T > C) T/T genotype was associated with
disease-free survival and overall survival. On the other hand,
the rs8108419 (G >A)G/Ggenotypewas associatedwith over-
all survival in the corresponding female cohort [9]. In another
study, in 2014, Li et al. [10] demonstrated that LMTK3 is more
frequently expressed in gastric cancer tissues compared to
normal tissue. In addition, a Kaplan–Meier analysis showed
that high levels of LMTK3 are a negative prognostic marker
in gastric cancer [10].
Colorectal cancer (CRC) is one of the leading causes of
cancer death worldwide [79]. Activation of Wnt/β-catenin sig-
nalling is a key driver of CRC and therefore an attractive target
for novel therapies. Naik et al. [11] used a kinome-wide siRNA
screen in human cells stably expressing a luciferase-basedWnt
reporter in the presence of Wnt3a to identify novel modulators
of the Wnt pathway [11]. The loss of LMTK3 was shown to
reduce β-catenin-regulated gene expression in both the primary
siRNA screen and an additional shRNA screen, suggesting that
LMTK3 plays an important role in Wnt signalling and CRC.
Similarly, in 2013 Shi et al. [12] found that high serum
LMTK3 positively correlates with tumour invasiveness and
tumour node metastasis (TNM) stage. The same research
group in 2014 also discovered that cellular LMTK3 levels posi-
tively correlatewith CRCmalignancies [13]. The authors found
that about 90% of CRC cells stained positive for LMTK3.
In bladder cancer cells, LMTK3 overexpression is positively
correlated with cancer progression and worse overall survival.
In 2020, Jiang et al. demonstrated that silencing of LMTK3
induces G2/M arrest, decreased cell growth and increased
apoptosis. Transwell assays also revealed that LMTK3
knockdown reduces invasiveness. They showed that MEK
(mitogen-activated protein kinase kinase, MAPKK) and
ERK1/2 (extracellular signal-regulated kinase 1/2) phos-
phorylation levels decrease upon LMTK3 siRNA treatment.
In a rescue experiment, the MAPK (mitogen-activated protein
kinase) inhibitor U0126 partially rescued the invasive, highly
proliferative phenotype of LMTK3-overexpressing cells, indi-
cating that driving MAPK activation is one pathway through
which LMTK3 achieves its oncogenic effects [14].
By contrast to the many oncogenic roles of LMTK3, an
unexpected function has been described in prostate cancer.
During the carcinogenesis of prostate cells, LMTK3 expression
is frequently downregulated at both the mRNA and protein
level, as opposed to the upregulation seen in many other can-
cers [15]. Overexpression of LMTK3 in prostate cancer cells
has been shown to reduce migration and invasion and




5LMTK3 siRNA had no impact on cell viability. Additionally,
when injected into nudemice, LMTK3-overexpressing prostate
cancer cells formed smaller tumours than wild-type cells. The
major driver of this was found to be apoptosis-related as
BAX (Bcl-2 associated X-protein) and Caspase-3 were upregu-
lated in the LMTK3-overexpressing tumour tissue and BCL2
(B-cell lymphoma 2) was downregulated. These results point
to a tumour suppressor role for LMTK3 in prostate cancer, con-
trary to the oncogenic roles seen in most other cancers. The
authors also found that p-P38 and p-JNK (c-Jun N-terminal
kinase) increased while p-AKT and p-ERK1/2 decreased
upon LMTK3 treatment and suggested that the observed
changes in MAPK subfamily phosphorylation may be the
driver of apoptosis in cells overexpressing LMTK3; however,
this was not determined experimentally [15].
In aggregate, the studies above underline the pressing
need for a better understanding of the elaborate mechanisms
involving LMTK3 in different tumour types.102184. The role of LMTK3 in breast cancer and
ERα regulation
In 2020, 2.3 million new cases of breast cancer were diag-
nosed and 684 996 deaths were recorded [79]. An improved
understanding of the molecular mechanisms underpinning
breast cancer development, progression and therapy resist-
ance is therefore essential to achieve improved outcomes in
breast cancer patients. Kinases and kinase-related proteins
are among the most investigated targets for the development
of new therapies to treat cancer. This is particularly true in
breast cancer where the roles of these proteins in both
tumour progression and response to treatment have been
deeply and widely investigated [16–18].
In 2011, a landmark study by Giamas et al. [19] revealed
that LMTK3 is a potent regulator of ERα. A kinome-wide
siRNA screen was performed to examine the impact of
depletion of different kinases on the expression of the ERα-
regulated gene, TFF1 (trefoil factor 1). LMTK3 knockdown
strongly reduced the expression of TFF1 in the primary
screen, in addition to GREB1 (growth regulation by oestrogen
in breast cancer 1) and PGR (progesterone receptor) secondary
screens. LMTK3 knockdown also induced a significant
reduction in ERα protein levels. Mechanistically, two distinct
pathways were found to be responsible. Firstly, LMTK3
affected the stability of ERα through phosphorylation, which
protected ERα from ubiquitin-mediated proteasomal degra-
dation (in vitro data). In addition, LMTK3 promoted ERα
transcription through the inhibition of PKC (protein kinase
C), which subsequently reduced the activity of the PKC sub-
strate, AKT through a decrease in Ser493 phosphorylation.
AKTpromotes the degradation of the ESR1 transcriptional acti-
vator, FoxO3 (forkhead box O3); therefore, the action of
LMTK3 on PKC resulted in the lifting of the inhibition on
ESR1 transcription, causing an increase in ERα expression
(figure 1). The relevance of this pathway in vivo was demon-
strated in a xenograft mouse model where LMTK3 siRNA
reduced the growth of tumours in mice initiated by ER+
MCF7 cells. Interestingly, LMTK3 was the only regulator of
ERα identified to have undergone recent positive Darwinian
selection, suggesting an important biological function. More-
over, given the unusual predisposition of humans to ER+
breast cancer, the positive selection of LMTK3 indicates thatit could be a key driver of this cancer subtype in humans
[19,20].
Clinical analyses also revealed the importance of LMTK3
as a predictive and prognostic marker in breast cancer. In a
follow-up study, Stebbing et al. [21] found that a high nuclear
and cytoplasmic LMTK3 abundance is a strong predictor of
more aggressive disease with poorer clinical outcomes. Two
intronic polymorphisms were also identified as important
markers of tumour recurrence as well as disease-free and
overall survival [19]. Tanioka et al. [22] detected increased
levels of LMTK3 in HER2-positive/ER-positive breast
cancer, while overexpression of LMTK3 positively correlated
with poor prognosis. These findings were further corrobo-
rated by a study by Asano et al. [23], supporting the
hypothesis that increased LMTK3 expression is an indicator
of poor prognosis in ER+ breast cancer.5. The role of LMTK3 in drug resistance
Shortly after the elucidation of the role of LMTK3 in ERα regu-
lation, Stebbing et al. [24] explored the function of LMTK3
in endocrine resistance. The authors found that tamoxifen-
resistant BT474 cells could be re-sensitized to tamoxifen in a
xenograft mouse model through inhibition of LMTK3.
Mechanistically, through awhole-genomemicroarray analysis,
it was demonstrated that LMTK3 silencing affects the
expression of a number of genes related to breast cancer
progression and importantly, a subset of genes involved in
tamoxifen resistance. These included c-MYC (proto-oncogene
c-MYC), HEY2 (hairy/enhancer-of-split related with YRPW
motif protein 2), SIAH2 (siah E3 ubiquitin-protein ligase 2)
and HSPB8 (heat shock protein beta-8). HSPB8 has been
shown to reduce autophagy in MCF7 cells, inhibiting cell
death in the presence of tamoxifen [81]. LMTK3 was found to
promote the translation of HSPB8 and overexpression of
LMTK3 reduced tamoxifen-induced cell death in MCF7 cells
by increasingHSPB8 abundance. Furthermore, LMTK3 protein
levels were found to positively correlate with endocrine resist-
ancewhere non-responders to aromatase inhibitors (AIs) had a
higher abundance of LMTK3 asmeasured using immunohisto-
chemistry of tumour tissue. Regions of the gene coding for
LMTK3 were also found to be amplified or deleted in cfDNA
(circulating free DNA) samples taken before and after therapy.
Changes in the LMTK3 gene correlated with relapse after
tamoxifen therapy. Taken together, these data suggest a role
for LMTK3 in both innate and acquired endocrine resistance
(figure 2) [24,25]. Cairns et al. [32] also showed the involvement
of LMTK3 in MIR2052HG-mediated AI resistance, which is
thoroughly discussed in a section below (the interplay between
non-coding RNAs and LMTK3).
The role of LMTK3 in chemotherapy resistance was further
investigated by Stebbing et al. [26]. The DNA topoisomerase II
inhibitor, doxorubicin, is an effective treatment for breast
cancer that works through inducing DSBs (double-strand
breaks) in DNA; however, resistance to therapy occurs rapidly
and is a major obstacle in breast cancer treatment. DSBs result
in γH2AX (phosphorylated histone H2AX) foci formation;
however, the formation of these foci was delayed by LMTK3
overexpression [26]. The pattern of ATM Ser1981 phosphoryl-
ation also differed with a smaller peak in LMTK3-
overexpressing cells that appeared more slowly and decayed





































































Figure 1. LMTK3 impacts on several facets of tumorigenesis. Graphical summary of the main mechanisms of oncogenic LMTK3 signalling. (a) ERα regulation by
LMTK3. LMTK3 regulates the activity of ERα at both the mRNA and protein level. LMTK3 reduces the activity of PKC, resulting in decreased levels of phosphorylated
AKT and increased binding of FOXO3 to the ESR1 promoter, indirectly increasing transcription of ERα. In addition, LMTK3 directly phosphorylates ERα, promoting
stability by protecting it from ubiquitin-mediated proteasomal degradation. Adapted from Johnson & O’Malley [19,80]. (b) LMTK3 stability. Like many other onco-
genic protein kinases, LMTK3 has recently been identified as an HSP90–CDC37 client protein requiring HSP90 for its folding and stability [33]. (c) The chromatin
remodelling and transcriptional co-repressor behaviour of LMTK3. LMTK3 binds PP1α and KAP1, promoting KAP1 Ser824 dephosphorylation, which results in chro-
matin condensation. Meanwhile, LMTK3 acts as a scaffolding protein, tethering the heterochromatin complex to the nuclear lamina. In doing so, LMTK3 promotes
transcriptional repression of tumour suppressor-like genes. Adapted from Xu et al. [29]. (d ) The role of LMTK3 in proliferation, invasion and migration. LMTK3
increases the abundance of integrin α5β1 by interacting with the adaptor protein GRB2. This interaction recruits SOS1, promoting the activation of Ras and
CDC42. This increases the activity of the transcription factor SRF, leading to increased binding at the ITGA5 and ITGB1 promoters, resulting in integrin α5 and
β1 upregulation [27]. (e) LMTK3 promotes cell–cell repulsion through phosphorylation of RCP. Phosphorylation of RCP by LMTK3 has been shown to be required
for the trafficking of EphA2 to the membrane via Rab14-positive endosomes. This phosphorylation event is therefore important in driving tumour dissemination
through contributing to cell–cell repulsion [28]. AKT/PKB, protein kinase B; CDC37, cell division cycle 37; CDC42, cell division cycle 42; EphA2, ephrin type-A
receptor 2; ERα, oestrogen receptor alpha; ESR1, oestrogen receptor 1; FOXO3, forkhead box O3; GRB2, growth factor receptor-bound protein 2; HSPB1, heat
shock protein beta-1; HSP90, heat shock protein 90; ITGA5, integrin subunit alpha 5; ITGB1, integrin subunit beta 1; KAP1, Krüppel-associated box domain-associated
protein 1; LMTK3, lemur tyrosine kinase 3; PKC, protein kinase C; PP1α, protein phosphatase 1α; Rab14, Ras-related protein Rab14; RCP, Rab-coupling protein; SOS1,





important for the derepression of p21, BAX and PUMA to pro-
mote cell cycle control and apoptosis when DSBs are detected.
The loss of this response in LMTK3-overexpressing cells
reduces the efficacy of chemotherapy drugs reliant on the
induction of DNA damage.
Stebbing et al. [26] additionally showed that cells overex-
pressing LMTK3 were less sensitive to doxorubicin as they
retained a higher viability and proliferation rate than wild-
type cells after treatment. This effect was also consistent
in vivo, where LMTK3-overexpressing MCF7 cells formed
larger subcutaneous tumours than wild-type MCF7 cells in
mice undergoing doxorubicin treatment. Transcriptome profil-
ing revealed that over 700 genes are differentially regulated by
doxorubicin, depending on LMTK3 expression levels. Many of
these are involved in DNA repair and oncogenesis. Notably,
HEY1 (hairy/enhancer-of-split related with YRPW motif
protein 1) is upregulated and SOX6 (SRY-box transcription
factor 6) is downregulated bywild-type cells upon doxorubicin
treatment; however, in cells overexpressing LMTK3, this
regulation is reversed (figure 2).
In another study, Gao et al. [35] sought to identify
mediators of IGF1R (insulin-like growth factor 1 receptor)
inhibitor resistance, since IGF1R inhibition has beenproposed as a strategy to slow cancer growth as it is an
important driver of survival and proliferative signalling
[82]. Unfortunately, the lack of biomarkers has made it diffi-
cult to identify patients that would benefit from IGF1R
inhibition; therefore, the authors explored relevant markers
of IGF1R inhibitor sensitivity using an siRNA screen.
Depletion of LMTK3 was shown to enhance the sensitivity
of both prostate and breast cancer cells to an IGF1R inhibitor
as demonstrated by a reduction in viability when exposed to
an IGF1R tyrosine kinase inhibitor. Since IGF1R promotes
proliferation and survival through Ras and LMTK3 is
known to activate the Ras pathway, it is likely that LMTK3
is conveying resistance to IGF1R inhibitors by initiating this
signalling intracellularly. This demonstrates another avenue
through which cancer may become resistant to small
molecule inhibitors, via changes in LMTK3 signalling [35].
Overcoming resistance would represent a great progress in
breast cancer management and LMTK3may be a valuable new
target. Moreover, LMTK3 could be used for the prediction of
treatment responses in order to personalize medicine and
identify patients likely to benefit from therapies in order
to avoid severe side effects in those unlikely to experience a
therapeutic benefit.
genes differentially regulated upon
tamoxifen treatment:
c-MYC, HSPB8, HEY2 and SIAH2







Figure 2. LMTK3-mediated endocrine and cytotoxic drug resistance in breast cancer. An increased LMTK3 abundance confers endocrine and chemotherapy resistance
in breast cancer. Interestingly, LMTK3 differentially regulates genes in the presence of tamoxifen or doxorubicin. Upon treatment, cells overexpressing LMTK3 modu-
late the expression of certain genes in the opposite direction to wild-type cells. For example, in wild-type MCF7 cells, HEY1 is upregulated and SOX6 is
downregulated when the cells are treated with doxorubicin; however, this is reversed in MCF7 cells overexpressing LMTK3. LMTK3 also modulates the expression
of genes involved in tamoxifen resistance, including c-MYC, HSPB8, HEY2 and SIAH2. c-MYC, proto-oncogene c-MYC; HEY1, hairy/enhancer-of-split related with YRPW
motif protein 1; HEY2, hairy/enhancer-of-split related with YRPW motif protein 2; HSPB8, heat shock protein beta-8; LMTK3, lemur tyrosine kinase 3; SIAH2, siah E3





6. The role of LMTK3 in proliferation,
invasion and migration
In addition to conferring drug resistance and regulating ERα,
LMTK3 also has roles in promoting invasiveness in breast
cancer. Xu et al. showed that LMTK3 induces the transcription
of the integrin subunits, integrin α5 and β1. The adaptor protein
GRB2 (growth factor receptor-bound protein 2) is an important
linker of receptor tyrosine kinases to the Ras signalling path-
way. The authors showed that LMTK3 is able to bind directly
to GRB2. GRB2 then recruits the guanine nucleotide exchange
factor, SOS1 (son of sevenless homologue 1), enabling it to acti-
vate both Ras and the Rho GTPase CDC42 (cell division cycle
42). This subsequently promotes the binding of SRF (serum
response factor) to the ITGA5 and ITGB1 promoters, resulting
in increased transcription (figure 1). The relevance of this path-
way was revealed in wound-healing assays and the Boyden
chamber assay where LMTK3 knockdown reduced migration,
whereas overexpression led to an increase in migration.
Additionally, LMTK3 was shown to promote focal adhesion
formation. Overexpression of LMTK3 increased motility, as
seen by relocalization of FAK (focal adhesion kinase) and vin-
culin to the leading edges of migrating cells. Adhesion to
collagen and fibronectin was also promoted by LMTK3 overex-
pression, whereas silencing of LMTK3 decreased adhesion.
ITGB1 expression is known to be of prognostic significance in
breast cancer where overexpression correlates with poor survi-
val [83]. Xu et al. [27] finally showed that LMTK3 abundance
correlates with ITGB1 expression in breast cancers through
immunohistochemistry, suggesting that LMTK3 promotes
invasiveness through ITGB1 transcription which reduces
survival in breast cancer.
More recently, Gundry et al. [28] found that LMTK3 pro-
motes cell–cell repulsion by altering EphA2 (ephrin type-A
receptor 2) trafficking. EphA2 is a receptor tyrosine kinase
and a driver of cancer cell dissemination. HGF (hepatocyte
growth factor) is known to promote invasion and migration
in cancer. The authors showed that HGF treatment of cellsresults in the phosphorylation of RCP (Rab-coupling protein)
at Ser435 by LMTK3 and EphA2 at Ser897 by AKT. These phos-
phorylations are both required for Rab14 (Ras-related protein
Rab14)-mediated recycling of EphA2 to themembrane. Knock-
out of either RCP or EphA2 in PDAC (pancreatic ductal
adenocarcinoma) mice models resulted in a reduction in inva-
sive behaviour. The authors suggested that the rerouting of
EphA2 from the constitutive Rab11-mediated fast recycling
pathway to the slower Rab14-mediated pathway, by LMTK3
and AKT phosphorylation of RCP and EphA2, respectively,
enables cell–cell repulsion through cytoskeletal responses. By
spending more time intracellularly, EphA2 was proposed to
partake in signalling pathways to promote repulsion; however,
more research is needed into the exact mechanism through
which this occurs. Overall, the authors demonstrated that
LMTK3 is a key component of this trafficking pathway where
its kinase activity is essential for the diversion of endosomal
cargo to a Rab14-dependent recycling pathway where it
drives HGF-mediated cell scattering (figure 1). Interestingly,
the RRSS435 phosphorylation site of RCP matches the recently
elucidated consensus sequence of LMTK3 that is presented
below, further confirming this finding.7. LMTK3 as a repressor of tumour
suppressor-like genes via chromatin
remodelling
In 2015, Xu et al. examined the nuclear effects of LMTK3,which
revealed an association between LMTK3 and repressive chro-
matin markers. Interestingly, LMTK3 brought about this
effect by working as a scaffold protein to facilitate the
interaction of the transcriptional co-repressor, KAP1 (Krüp-
pel-associated box domain-associated protein 1) and a KAP1
phosphatase, PP1α (protein phosphatase 1α) [29]. The authors
demonstrated that LMTK3 localizes to chromatin in an ERα-
independent manner in both the ER+ cell line, MCF7 and the
TNBC line, MDA-MB-231. Immunoprecipitation revealed an
royalsocietypublishing.org/journal/rsob
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8interaction between LMTK3 and KAP1. In vitro kinase assays,
however, did not indicate that LMTK3 phosphorylates KAP1.
It was instead shown that the KAP1 phosphatase, PP1α, is an
important stabilizer of the LMTK3–KAP1 interaction and that
the three proteins colocalize in the nucleus. Further to this,
the authors demonstrated that PP1α dephosphorylates
LMTK3-bound KAP1 at Ser824, which results in transcriptional
silencing and chromatin condensation through the trimethyla-
tion of Histone H3 lysine 9 (H3K9me3). Moreover, the
interaction leads to the tethering of the H3K9me3-marked het-
erochromatin to the nuclear periphery (figure 1). Overall,
LMTK3, KAP1 and PP1α are co-expressed in the majority of
breast cancers where they collaborate to repress tumour sup-
pressor-like genes through the remodelling of chromatin,
which promotes a more aggressive phenotype.Biol.11:2102188. The interplay between non-coding RNAs
and LMTK3
Besides the numerous protein interactions, LMTK3 also takes
part in some interesting pathways involving non-coding
RNAs. The miRNAs miR-34a and miR-182 have been shown
to target LMTK3 transcripts, reducing the abundance of
LMTK3 mRNA and protein. Functionally, this results in a
decrease in proliferation, invasion and migration. It was found
that LMTK3 reduces the abundance of miR-34a, miR-182 and
miR-196-a2 through sequestration of their respective pri-
miRNAs, inhibiting further processing. Through doing this,
LMTK3 avoids miRNA-mediated downregulation. LMTK3
was shown to bind to DEAD-box RNA helicase p68 (DDX5)
and the pri-miRNAs of these three miRNAs, promoting their
processing into pre-miRNA but inhibiting further processing
into functional miRNAs, thereby protecting itself from down-
regulation [30,31]. miR-34a is known to have a tumour
suppressor role; however, this study further demonstrated that
the oncogenic miRNA, miR-182, also has a tumour suppressor
role in breast cancer cells overexpressing LMTK3, highlighting
the complex signallingnetwork surroundingLMTK3 regulation.
The long non-coding RNA, MIR2052HG, has also been
shown to play a role in resistance to endocrine therapy through
the upregulation of LMTK3. Ingle et al. had previously demon-
strated that MIR2052HG and ESR1 transcription are induced
by oestrogen and AIs in some SNP genotypes. Further, they
observed that MIR2052HG silencing results in a decrease
in ERα expression. The increase in ERα abundance when
MIR2052HG is overexpressed was demonstrated to be via the
AKT/FOXO3 pathway, which increased transcription of ESR1
through inhibition of ERα degradation. As LMTK3 is involved
in ERα regulation through both of these pathways, Cairns et al.
explored the role of MIR2052HG in LMTK3 regulation where
they found that MIR2052HG silencing strongly reduces the
expression of LMTK3. Moreover, they found that LMTK3 over-
expression could rescue the low proliferation rate of cells with
downregulated MIR2052HG. MIR2052HG was found to pro-
mote LMTK3 transcription through recruitment of EGR1
(early growth response 1) to the LMTK3 promoter, increasing
the abundance of ERα through promoting transcription and
inhibiting degradation [32]. The authors also hypothesized
that LMTK3 upregulation may be responsible for the AI resist-
ance conveyed by MIR2052HG overexpression. They found
LMTK3 to be upregulated in cells with wild-type MIR2052HG
upon AI treatment; however, LMTK3 was downregulated incells with the MIR2052HG variant genotypes, rs4476990 and
rs3802201 after treatment with AIs. Cells with the variant geno-
types were also more sensitive to aromatase inhibition than
wild-type cells. In addition, LMTK3overexpressiondesensitized
cells to AIs. These findings suggest that LMTK3 is upregulated
upon treatment with AIs through MIR2052HG and EGR1
where it may contribute to AI resistance through ERα upregula-
tion and stabilization [32]. Overall, these studies emphasize the
breadth of the LMTK3 signalling network, highlighting the
importance of further research into LMTK3 pathways.9. Interrogating the LMTK3 signalling
circuits
To further decipher the downstream pathways of LMTK3, a
positional scanning peptide library (PSPL) approach was
taken to determine the consensus phosphorylation sequence
of LMTK3. Initially, the consensus peptide substrate (LMTK3-
tide: WRRFSFCMC) was designed and then radiolabelled in
vitro kinase assays of the LMTK3-tide with amino acid substi-
tutions were carried out, revealing a strict requirement for
arginine (R) residues at positions -3 and/or -2 [33]. The results
were corroborated by a PepChip kinase assay, which also high-
lighted the importance of arginine at positions -3 and/or -2 [33].
Interestingly, as discussed above, this consensus sequence
matched those seen in RCP and one of the putative phosphoryl-
ation sites in KCC2, further confirming the validity of this
approach [28,73]. It is noteworthy that phosphorylation sites
beyond the canonical LMTK3 consensus sequence may also
be substrates of LMTK3 as is seen with various other kinases.
By employing a quantitative mass spectrometry analysis
using stable isotope labelling of amino acids in cell culture
(SILAC), precious phosphoproteomic data were also gathered
on LMTK3-regulated proteins in MCF7 breast cancer cells. A
multitude of direct and indirect targets of LMTK3 were
uncovered with many hits having known roles in promoting
oncogenesis. HSP27 (heat shock 27 kDa protein) was among
the most significant hits, additionally appearing in the Pep-
chip microarray and in vitro kinase assays. HSP27 has been
previously implicated in breast cancer progression and
therapy resistance; therefore, the phosphorylation at Ser15
and Ser82 by LMTK3 may indicate an important pathway
that requires further elucidation [84].
Importantly, the data collected from these complimentary
approaches will help decode the complex signalling path-
ways surrounding LMTK3, enabling their integration into
the wider network of cancer signalling. With the knowledge
that LMTK3 is heavily involved in promoting the progression
and development of both ER+ and triple-negative breast
cancer, further research into candidate substrates will be cru-
cial to develop therapeutics targeting these pathways to
improve cancer treatment.10. The translational potential of LMTK3 in
cancer
As described above, LMTK3 has been repeatedly demon-
strated to partake in oncogenic processes, suggesting that
inhibition of LMTK3 may represent a useful therapeutic
tool. Although earlier studies have attempted to develop
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Figure 3. The mechanism of action of C28. LMTK3 has emerged as a critical mediator of oncogenic functions and is therefore considered to be a promising target of
anti-cancer therapies. The small molecule C28 was recently identified as a potent and selective LMTK3 inhibitor. C28 acts by inducing the proteasome-mediated
degradation of LMTK3 through chaperone deprivation. Furthermore, the depletion of LMTK3 by C28 results in microtubule instability with subsequent G2/M cell cycle
arrest and cell death through downregulating NUSAP1 and the NUSAP1-regulated protein CDK1. This also reduces the phosphorylation of βIII tubulin at Ser172





pharmacological data [45–48,74]; therefore, the need for
potent and selective LMTK3 inhibitors remained. However,
in 2020, by adopting a robust high-throughput screening
approach combined with various biochemical, biophysical
and cellular assays, C28 was identified as a potent, orally
available and highly selective ATP-competitive inhibitor
targeting LMTK3. Pre-clinical data demonstrated strong
anti-cancer activity in the NCI-60 cell line panel and exper-
iments in xenograft mouse models revealed that the
potency and selectivity translated well in vivo [33].
Interestingly, while studying the mechanism of action of
C28, we discovered that LMTK3 abundance decreasesfollowing prolonged treatment of cells with C28. LMTK3
was found to be an HSP90–CDC37 (heat shock protein
90-cell division cycle 37) client protein, which requires
HSP90 for folding and stability (figure 1). Experiments
revealed that C28 has a dual mechanism of action, both com-
peting for the ATP binding site of LMTK3 and promoting
LMTK3 degradation through chaperone deprivation
(figure 3). By depriving LMTK3 of HSP90, C28 promotes
kinase instability and proteasomal degradation of LMTK3.
With oncogenic roles as both a kinase and scaffold protein,
this dual mechanism of action will probably provide more




10Additionally, LMTK3 was found to directly phosphorylate
CDC37; therefore, research is needed into the role of
LMTK3 on the HSP90–CDC37 chaperone system as a
whole [33].
Further characterization ofC28 revealed an interesting effect
on the cell cycle [34]. In addition to LMTK3 inhibition, C28 was
found to induce apoptosis and G2/M arrest in breast cancer
cells, indicating that C28 may exert its anti-cancer effects
through an additional mechanism. This phenotype reflected
that of cells treated with microtubule destabilizing drugs,
suggesting that C28 interferes with microtubule dynamics.
This was confirmed through immunofluorescence, which
showed abnormalities in the mitotic spindle in metaphase
cells after treatment with C28. C28 also caused a dose-
dependent decrease in insoluble, polymerized tubulin. C28
does not bind directly to tubulin; therefore, a proteomics
approach was taken to elucidate the mechanism. Both siRNA
against LMTK3 and C28 reduced the abundance of the
microtubule-associated protein NUSAP1 (nucleolar and spin-
dle associated protein 1), the NUSAP1-regulated protein
CDK1 (cyclin-dependent kinase 1) and decreased the level of
phosphorylated βIII tubulin at Ser172. The phenotype of cells
deficient in NUSAP1 is consistent with that of C28-treated
cells. Immunoprecipitation demonstrated that LMTK3 stably
interacts with NUSAP1, indicating that the C28-mediated
NUSAP1 depletion is likely a result of LMTK3 inhibition and
not an off-target effect of C28; however, more research is
needed into the exact mechanism (figure 3).
Overall, the substantial volume of functional and mechan-
istic pre-clinical data presented by these studies, alongwith the
newly solved structure of LMTK3, will aid in optimizing
LMTK3 inhibitors with prospective value to cancer patients.11. Concluding remarks
The studies discussed above portray LMTK3 as an exception-
ally versatile protein kinase and highlight its complex role
both in normal physiology and pathological conditions, most
notably cancer. So far we are probably only aware of a small
proportion of the LMTK3-mediated roles across different cell
types and further investigation is certainly required to unveil
the full functional spectrum of LMTK3 in the coming years.
Although several groups have examined the physiological
role of LMTK3, the majority of studies are principally focused
on cancer, while a large percentage of this work is related to
clinical studies. Particular emphasis should therefore be
placed on mechanistic investigations that will shed more
light on the functions of LMTK3. For example, very little is
known about the upstream regulation of LMTK3 and elucidat-
ing these mechanisms will help define the greater network in
which LMTK3 acts. Moreover, optimization of LMTK3 inhibi-
tors on the basis of the work that led to the identification and
characterization of C28 presents great translational potential.
In summary, research on LMTK3 could have a huge impact
on patients, while being beneficial to the scientific community
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